S
Santhera Pharmaceuticals Holding AG
SIX:SANN
Santhera Pharmaceuticals Holding AG
SIX:SANN
Price:
9.32 CHF
-0.53%
Updated:
May 3, 2024
Santhera Pharmaceuticals Holding AG
Net Income (Common)
|
Santhera Pharmaceuticals Holding AG
Net Income (Common) Peer Comparison
Comparables:
ADCT
CRSP
BSLN
IDIA
KURN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
S
|
Santhera Pharmaceuticals Holding AG
SIX:SANN
|
Net Income (Common)
-CHf71.1m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Net Income (Common)
-$240.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Net Income (Common)
-$153.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Net Income (Common)
CHf10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Net Income (Common)
-CHf827.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Net Income (Common)
-CHf13.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
See Also
What is Santhera Pharmaceuticals Holding AG's Net Income (Common)?
Net Income (Common)
-71.1m
CHF
-71.1m
CHF
Based on the financial report for Dec 31, 2022, Santhera Pharmaceuticals Holding AG's Net Income (Common) amounts to -71.1m CHF.
What is Santhera Pharmaceuticals Holding AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-7%
-7%
Over the last year, the Net Income (Common) growth was -28%. The average annual Net Income (Common) growth rates for Santhera Pharmaceuticals Holding AG have been -55% over the past three years , -7% over the past five years .
You don't have any saved screeners yet
